Combination Therapy by Transarterial Injection of Miriplatin-Iodized Oil Suspension with Microwave Ablation for Medium-Sized Hepatocellular Carcinoma: the Preliminary Experience.
Hepatocellular carcinoma
Medium-sized
Microwave ablation
Miriplatin
Transarterial injection
Journal
Interventional radiology (Higashimatsuyama-shi (Japan)
ISSN: 2432-0935
Titre abrégé: Interv Radiol (Higashimatsuyama)
Pays: Japan
ID NLM: 101745449
Informations de publication
Date de publication:
01 Mar 2022
01 Mar 2022
Historique:
received:
08
03
2021
accepted:
16
08
2021
entrez:
1
8
2022
pubmed:
2
8
2022
medline:
2
8
2022
Statut:
epublish
Résumé
To evaluate the feasibility and safety of transarterial injection of a miriplatin-iodized oil suspension combined with Emprint miriplatin-iodized oil suspension-microwave ablation in patients with medium-sized (3-5 cm) hepatocellular carcinomas. This retrospective study included a total of 11 patients with 12 hepatocellular carcinomas (mean size, 3.6 ± 0.6 cm) underwent miriplatin-iodized oil suspension-microwave ablation. Microwave ablation was performed under the guidance of computed tomography fluoroscopy following transarterial miriplatin-iodized oil suspension injection on the same day. Technical success, complications, and local tumor progression were assessed. The primary and secondary technical success rates were 75.0% and 100%, respectively. The number of treatment sessions per nodule was 1.25 ± 0.45. A total 15 sessions were required to achieve technical success (one session in nine lesions, two sessions in three lesions). Two major complications (pneumothorax [n = 1] and hemorrhage [n = 1]) occurred (2/15, 13.3%). No local tumor progression was observed during the follow-up period (mean 12.0 ± 2.0 months, range 2.7-23.9 months). Miriplatin-iodized oil suspension-microwave ablation for medium-sized hepatocellular carcinomas can be safely performed with good local control.
Identifiants
pubmed: 35911877
doi: 10.22575/interventionalradiology.2021-0009
pmc: PMC9327324
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1-8Informations de copyright
© 2022 Japanese Society of Interventional Radiology.
Déclaration de conflit d'intérêts
None
Références
Rofo. 2017 Nov;189(11):1055-1066
pubmed: 28834968
Am J Gastroenterol. 2012 Apr;107(4):569-77; quiz 578
pubmed: 22158026
Int J Hyperthermia. 2018 Dec;34(8):1351-1358
pubmed: 29720001
AJR Am J Roentgenol. 2010 Feb;194(2):530-5
pubmed: 20093620
Semin Intervent Radiol. 2015 Dec;32(4):335-8
pubmed: 26622094
Int J Hyperthermia. 2018 Dec;35(1):90-96
pubmed: 29923441
Radiology. 2014 Oct;273(1):241-60
pubmed: 24927329
Diagn Interv Radiol. 2018 Jul;24(4):219-224
pubmed: 29792289
J Gastroenterol. 2005 Feb;40(2):171-8
pubmed: 15770401
Invest New Drugs. 2012 Oct;30(5):2015-25
pubmed: 22187203
Br J Radiol. 2019 Jul;92(1099):20180864
pubmed: 30845823
J Vasc Interv Radiol. 2007 Jul;18(7):856-61
pubmed: 17609444
Jpn J Radiol. 2013 Jun;31(6):424-7
pubmed: 23525952
Ann Surg Oncol. 2011 Jun;18(6):1624-9
pubmed: 21445671
Jpn J Radiol. 2016 Sep;34(9):640-6
pubmed: 27455985
World J Hepatol. 2015 May 18;7(8):1054-63
pubmed: 26052394
Cardiovasc Intervent Radiol. 2013 Aug;36(4):1144-6
pubmed: 23354960
J Vasc Interv Radiol. 2016 Feb;27(2):268-74
pubmed: 26669701
J Vasc Interv Radiol. 2019 Oct;30(10):1533-1543
pubmed: 31471190
J Int Med Res. 2018 Jul;46(7):2650-2657
pubmed: 29683022
N Engl J Med. 2019 Apr 11;380(15):1450-1462
pubmed: 30970190
Jpn J Radiol. 2021 Apr;39(4):376-386
pubmed: 33150469
Hepatol Res. 2013 Sep;43(9):942-9
pubmed: 23301851
Bone Marrow Transplant. 2013 Mar;48(3):452-8
pubmed: 23208313
J Vasc Interv Radiol. 2010 Aug;21(8 Suppl):S204-13
pubmed: 20656230
Cancer. 2005 Jan 15;103(2):299-306
pubmed: 15578688
AJR Am J Roentgenol. 2020 Jul;215(1):223-234
pubmed: 32255691